Maria Dobek
CIK: 0002032671
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (50.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
JANX
Janux Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- May 11, 2026JANX
Janux Therapeutics, Inc.
Sale(S)Direct2K shares at avg. $14.17$29K - Jan 2, 2026JANX
Janux Therapeutics, Inc.
Sale(S)Direct1.5K shares at avg. $13.73$20K - Jan 2, 2026JANX
Janux Therapeutics, Inc.
Award(A)Direct18.9K shares- - Jan 2, 2025JANX
Janux Therapeutics, Inc.
Award(A)Direct14K shares-
1-4 of 4 transactions
About Dobek Maria
Dobek Maria (SEC CIK 0002032671) files insider reports with the SEC as Vice President, Accounting of Janux Therapeutics, Inc. (JANX).
Signal8 holds 3 ownership filings by Dobek Maria, all Form 4s, filed between Jan 3, 2025 and May 13, 2026. Those filings report 4 transactions, from Jan 2, 2025 to May 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Dobek Maria's filings is in SAN DIEGO, CA.
Recent filings by Dobek Maria
Other insiders filing for Janux Therapeutics, Inc. (JANX)
- Campbell David Alan, President and CEO
- RA CAPITAL MANAGEMENT, L.P., Director
- Simson Jake, Director
- Kung Winston, Director
- Hernday Natasha, Director
- DOBMEIER ERIC, Director